How long will it take for ivonib (ivitinib) to be included in medical insurance? What is the market situation of generic drugs and what are their prices?

Avosidenib, a precision treatment drug for IDH1 mutated cancers, has shown significant clinical effects in the treatment of acute myeloid leukemia (AML), cholangiocarcinoma and myelodysplastic syndrome in recent years. By specifically inhibiting the activity of isocitrate dehydrogenase-1 (IDH1), the drug effectively reduces the abnormal accumulation of the tumor metabolite 2-hydroxyglutarate (2-HG), thereby interfering with the abnormal metabolic pathways of tumor cells and bringing new treatment hope to patients.

However, the high price of ivonib and the fact that it has not yet been included in the national medical insurance catalog have undoubtedly brought a heavy financial burden to patients and their families. For patients, when the medical insurance reimbursement policy for ivonib will be ushered in, it has become an issue of urgent concern.

The adjustment of the medical insurance catalog is a rigorous and complex process, which involves comprehensive consideration of multiple dimensions such as drug efficacy evaluation, safety considerations, cost-benefit analysis, and actual patient needs. Therefore, it is not yet possible to give an exact timetable for when ivonib will be included in medical insurance. Patients and their families need to pay close attention to the relevant policy developments of the National Medical Insurance Bureau to keep abreast of the medical insurance inclusion status of ivonib and the specific reimbursement policy.

While waiting for adjustments to medical insurance policies, patients and their families can consider generic drugs as an alternative. Currently, in the Laotian market, the generic version of ivonib produced by Lucius Pharmaceuticals has been approved by the Laotian government. Its price is more affordable than the original drug, with a box of the same specification costing about 4,000 yuan. However, when choosing generic drugs, patients and their families must maintain a high degree of vigilance and ensure that the purchased drugs come from formal and legal sources to ensure the quality and safety of the drugs.

It is worth noting that ivonib is a prescription drug and its use must strictly follow the instructions of a doctor. Before taking medication, patients should consult a professional doctor in detail to ensure that the medication is suitable for their condition and to understand possible adverse reactions and countermeasures. At the same time, during the treatment process, patients should have regular follow-up visits and provide timely feedback to the doctor on the treatment effects and physical condition, so that the doctor can adjust the treatment plan according to the condition.

To sum up, the medical insurance inclusion status of ivonib (ivitinib) still needs to wait for further policy adjustments from the National Medical Insurance Bureau. During this period, patients and family members can consider choosing generic drugs as an alternative, but they must ensure that the purchasing channels are formal and legal.

References:

https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tibsovo